Document: RESEARCH

Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells

Márcia Cristina Oliveira da Rocha1, Patrícia Bento da Silva2, Marina Arantes Radicchi1, Bárbara Yasmin Garcia Andrade1, Jaqueline Vaz de Oliveira2, Tom Venus3, Carolin Merker3, Irina Estrela-Lopis3, João Paulo Figueiró Longo2 and Sônia Nair Bão1*

Abstract

Background: Metastasis causes the most breast cancer-related deaths in women. Here, we investigated the antitumor effect of solid lipid nanoparticles (SLN-DTX) when used in the treatment of metastatic breast tumors using 4T1-bearing BALB/c mice.

Results: Solid lipid nanoparticles (SLNs) were produced using the high-energy method. Compritol 888 ATO was selected as the lipid matrix, and Pluronic F127 and Span 80 as the surfactants to stabilize nanoparticle dispersion. The particles had high stability for at least 120 days. The SLNs' dispersion size was 128 nm, their polydispersity index (PDI) was 0.2, and they showed a negative zeta potential. SLNs had high docetaxel (DTX) entrapment efficiency (86%), 2% of drug loading and showed a controlled drug-release profile. The half-maximal inhibitory concentration (IC50) of SLN-DTX against 4T1 cells was more than 100 times lower than that of free DTX after 24 h treatment. In the cellular uptake test, SLN-DTX was taken into the cells significantly more than free DTX. The accumulation in the G2-M phase was significantly higher in cells treated with SLN-DTX (73.7%) than in cells treated with free DTX (23.0%), which induced subsequent apoptosis. TEM analysis revealed that SLN-DTX internalization is mediated by endocytosis, and fluorescence microscopy showed DTX induced microtubule damage. In vivo studies showed that SLN-DTX compared to free docetaxel exhibited higher antitumor efficacy by reducing tumor volume (p < 0.0001) and also prevented spontaneous lung metastasis in 4T1 tumor-bearing mice. Histological studies of lungs confirmed that treatment with SLN-DTX was able to prevent tumor. IL-6 serum levels, ki-67 and BCL-2 expression were analyzed and showed a remarkably strong reduction when used in a combined treatment.

Conclusions: These results indicate that DTX-loaded SLNs may be a promising carrier to treat breast cancer and in metastasis prevention.

Keywords: Cellular uptake, 4T1, NIH-3T3, IL-6, BCL-2, Ki-67 and antitumor effect

Background

Breast cancer is the most prevalent malignant tumor in women and a major cause of mortality among women worldwide. Metastasis causes the majority of breast cancer-related deaths. Chemotherapy is used to prolong patient survival and prevent recurrence and metastasis [1]. Taxanes (docetaxel or paclitaxel) are examples of chemotherapies that are used in these contexts [2].

Docetaxel (DTX) is a lipophilic anticancer agent and a semi-synthetic taxane derived from the European tree Taxus baccata [3]. Docetaxel has been approved by the Food and Drug Administration (FDA) and is widely used for different types of cancer, such as breast cancer,
ovarian cancer, prostate cancer, non-small-cell lung cancer, gastric adenocarcinoma, and others [4]. DTX acts by binding reversibly to microtubules, promoting transitory structure stabilization, leading to cell cycle arrest. Therefore, docetaxel is a cytostatic drug for the control of tumor tissue growth [5].

In terms of clinical importance, taxane has an important role in metastatic breast cancer treatment. DTX showed some improved survival outcomes regarding metastatic disease when compared with other chemotherapeutic agents [6]. However, the clinical administration of intravenous DTX has been limited due to its poor aqueous solubility (4.93 µg/mL in purified water), high lipophilicity (logP = 4.1), low bioavailability and high toxicity. To increase the solubility of DTX, the pharmaceutical industry developed some formulations containing surfactants, such as Tween-80, and/or alcohol, to combat these pharmacotechnical problems. Nevertheless, as highly reactive components, these formulations cause some adverse reactions in patients, including hypersensitivity, neurotoxicity, musculoskeletal toxicity and fluid retention [7]. In order to reduce these side effects, researchers are developing different types of drug delivery systems (DDS), such as nanoparticles (NPs), to overcome these drawbacks related to DTX. Drug delivery systems, such as solid lipid nanoparticles [8], liposomes [9], nanoemulsions [10], and polymeric micelles [11] could improve DTX’s therapeutic effect, increase stability, and boost drug biocompatibility.

Among the different types of lipid nanostructures, solid lipid nanoparticles (SLNs) are an attractive DDS due to their high structural stability and biocompatibility in comparison to nanoemulsions and are considered a less toxic alternative to polymer-based nanoparticles [12]. SLNs are made from physiologically tolerable lipid components, which remain in the solid state at room and body temperature [13]. Some advantages of SLNs include low toxicity, controlled drug release, physical stability, large-scale production, protection of incorporated drug, high drug loading, low cost, avoidance of organic solvents in preparation, biodegradability, biocompatibility and capability of incorporating hydrophilic and hydrophobic compounds [14, 15]. Thus, the development of docetaxel-loaded SLNs (SLN-DTX) provides a good alternative carrier to prolong DTX plasma circulation half-life, prevent drug toxicity and increase DTX delivery to tumor tissues [16].

Therefore, in accordance with the literature review presented, the aim of this study was to evaluate the efficiency of SLN-DTX in vitro and in vivo in a tumor xenografts model induced in female BALB/C mice.

Results and discussion
Docetaxel is one of the most important chemotherapeutical drugs available nowadays. Its best-known pharmacutical form is Taxotere®, which is a product containing docetaxel and two excipients ingredients, ethanol and tween 80. This is a successful product with billionaire revenues, however some improvements on the product formulation are required by the medical community. It is a consensus that ethanol administration should be avoided to reduce the potential toxicity of the formulation. Thus, several research centers are investing efforts to produce a commercially viable Docetaxel formulation that could overcome the actual formulations drawbacks.

Our research group developed different types of nanocarriers that could be useful for this propose. For the present article, we design a Solid Lipid Nanoparticle that could efficiently entrap Docetaxel without any organic solvent, and that the preparation process was carried out entirely in aqueous systems, aiming the industrial scale-up process. As highlight of our results, we could say that the SLN developed had an encapsulation rate higher than 85%, result that is difficult to be reproduced in other carrier systems, such as liposomes. In addition, as presented in our results, this Solid Lipid Nanoparticle had excellent results in terms of tumor control and prevention of distant lung metastasis. This second is really important to highlight because the experiments were conducted in a 4T1 tumor bearing mice, which has a strong metastatic profile, and we consider a differential result in comparison to others docetaxel nanocarriers.

Preparation, characterization and in vitro release of SLNs
Solid lipid nanoparticles were prepared by high-energy method. Compritol was selected as the solid lipid, and the selected surfactants were Span 80 and Pluronic F127. This lipid phase was chosen based on some reports in the literature [17–19], and the final formulation was established as the best formulation that remained stable after the incorporation of docetaxel. The use of two surfactants combined (in this study we used Span 80 and Pluronic F127) instead of only one is more effective, reducing the interfacial tension in nanoparticles to prevent their aggregation, producing smaller and more stable nanoparticles [20]. A study comparing Pluronic F68 and Pluronic F127 showed that nanoparticles made with Pluronic F127 produce a stronger hydrophobic interaction with DTX than when made with Pluronic F68. This is due to the lower HLB (hydrophilic–lipophilic balance) value of Pluronic F127. It results in a better suspension preparation and could prevent nanoparticle aggregation [21]. Thus, it is important to choose suitable surfactants for SLN preparations. Figure 1a shows the schematic...
model illustration of docetaxel-loaded solid nanoparticles and Fig. 1b shows the docetaxel structure. The model was based on the lipophilicity of docetaxel, which in theory would be dispersed in the SLNs’ lipid core [14, 22].

The particles’ charge interaction with medium is measured as the zeta potential parameter. It is considered as one reference for colloidal stability. As a repellent surface force, this parameter contributes to keeping the dispersed nanoparticles separate, thereby assisting in the formulation stability [23]. The zeta potential value of blank-SLN and SLN-DTX were $-11$ and $-15$ mV, respectively. There were no significant differences in zeta potential value between blank and SLN-DTX, suggesting that DTX incorporation did not alter colloidal stability. The negative surface charge induces electrostatic repulsion. It can ensure the physical stability of nanoparticles during storage and can prevent the formation of aggregates [24]. In addition, negative charged particles tend to have an increased plasma circulation time [25, 26]. The mean hydrodynamic diameter of the SLN-DTX was $128 \pm 2.2$ nm with a polydispersity index of $0.153 \pm 0.02$. The assessment of the colloidal stability in physiological fluids is important. Thus, we performed the SLN-DTX interaction with biological media (Additional file 1: Figure S1). The DH, PDI and zeta potential remain stable at sample up to 7 days after formulation, with the exception of zeta potential in serum ($p > *0.1$), as result of protein aggregation and corona formation. When nanoparticles are added to serum they enter in contact with albumin and other proteins, forming the protein corona, and protein adsorption strongly occurs. Some authors have demonstrated that the formation of protein layer destabilizes the nanoparticles, which affects the surface charge distribution [27].

Studies demonstrate that PDI values lower than 0.2 indicate a homogeneous distribution and uniformity of nanoparticles [28, 29]. Thus, zeta potential, size and PDI did not show significant changes, indicating that SLN-DTX are stable over the 120 days (Fig. 2a). Figure 2b shows the storage stability study of SLN-DTX. Mean particle size was $126 \pm 5.0$ nm with PDI of $0.19 \pm 0.01$, and zeta potential was $-15 \pm 0.5$ mV. These results demonstrate the suitable stability of SLN-DTX, but with a significant change only during the fourth measurement of particle size ($p^{****} < 0.0001$). After being subjected to this stress test, samples remained stable after abrupt temperature change.

Medium-sized nanoparticles of less than 500 nm with a spherical shape have enhanced internalization efficiency in the cell. Spherical particles have the right shape that allows them to attach onto the cells and offer a high volume of the incorporated drug [30]. According to TEM micrographs, blank-SLN and SLN-DTX are spherical and uniform, which demonstrated that the entrapment of DTX would not significantly influence the shape of the SLNs. The mean particle size of blank-SLNs is $110$ nm, and of SLN-DTX is $120$ nm (Fig. 2c). These results are in agreement with DLS measurements.

Entrapment efficiency and the drug loading of SLN-DTX were $86 \pm 2.4\%$ and $2\% \pm 0.12\%$, respectively. The EE% and DL% depends on the composition of the lipid matrix and its crystalline state. It has been reported that in lipid-based drug delivery systems, the binding energy of the drugs with the lipids plays a key role in successful encapsulation of drugs [31]. The formulation (SLN-DTX) presented similar entrapment efficiency and drug loading
comparing to works previously reported in the literature [32, 33].

The in vitro drug release profiles of SLN-DTX were evaluated at the pH values of 7.4 and 5.0 to mimic the physiological pH of blood and the acidic intracellular environment of the tumor cells, respectively (Fig. 2d). We identified an initial burst effect release, followed by controlled release, in SLN-DTX at both pHs. The SLN-DTX drug accumulation release percentages reached over 77% at pH 5.0 and 69% at pH 7.4 in 10 days, respectively. No differences were observed. The prolonged release suggests homogeneous entrapment of the DTX throughout the system. It was possible to observe this strong interaction in the results of DSC, Raman and FTIR. The benefit of the prolonged release system could be the reduction of the dose and drug administration by maintaining drug concentrations in a therapeutic window over a long period of time [34]. This profile affirms the applicability of SLNs as a promising drug carrier.

Fourier transform infrared and raman spectroscopy
The spectroscopy technique was used in the infrared region to determine the interaction level of functional groups in the active material (docetaxel) and the
carrier system. The FTIR assignments and frequencies are shown in Additional file 2: Table S1. Additional file 3: Figure S2 shows the FTIR spectrum of DTX. The FTIR spectra are given in Fig. 3-a for SLN-DTX, blank-SLN, free DTX and SLN components: Span 80, Compritol and Pluronic F127. The DTX FTIR spectrum showed bands at 3369 cm\(^{-1}\) (\(\nu_{O-H}\) and \(\nu_{N-H}\)), 1437 cm\(^{-1}\) (\(\nu_{C=O}\)), 2982 cm\(^{-1}\) (\(\nu_{as CH}\)), 2937 cm\(^{-1}\) (\(\nu_{s CH}\)), 709 cm\(^{-1}\) (\(\delta_{CH}\)), two bands assigned to the vibrational mode \(\nu_{C=0}\), one at 1738 cm\(^{-1}\) and another at 1709 cm\(^{-1}\), relative to carbonyl groups of ester and ketone, respectively [2]. Blank-SLN FTIR spectra were very similar to SLN-DTX analysis. The DTX characteristic bands were not observed in SLN-DTX FTIR spectra. The DTX is present in low concentrations in the NLS-DTX, and this makes it difficult to detect the bands assigned to the drug and to assess changes in the frequency of them, FTIR technique, therefore doesn’t confirm the presence of the drug in the carrier. Similar results were analyzed by Albano et al. [35] in a study that observed the absence of the DTX band in lipid-polymeric nanoparticle by FTIR technique. During preparation of the nanoparticles, there is a possibility of different physical–chemical interactions, such as the formation of hydrogen bonds between SLN components and drug. This interaction influences the bond stiffness and so alters the frequency of vibration [36, 37]. Solid lipids may be interacting with DTX groups. However, the FTIR spectrum of SLNs shows the characteristic peaks of similar functional groups, confirming the successful formulation of nanoparticles without any chemical interaction [38].

The Raman spectral signature of our DTX was in agreement with previous reports [39] (Additional file 4: Figure S3 and Additional file 5: Table S2). Figure 3b shows DTX spectral bands at 620 and 1006 cm\(^{-1}\), which are attributed to the aromatic vibrations of monosubstituted benzene, while vibrational bands at 1605, 1632, and 1715 cm\(^{-1}\) were respectively assigned to the ester, aromatic stretch (\(\nu_{C=C}\)), carbonyl groups present in the DTX drug. In the region of 1200–1430 cm\(^{-1}\), the secondary alcohol group is present. There are also broad bands with shoulders in the region of 1200–1500 cm\(^{-1}\), which are attributed to the deformation of CH\(_2\) and CH\(_3\) [40]. New bands appeared in the SLN-DTX spectra by comparison with the blank-SLN spectra (Fig. 3b). These bands correspond to the presence of docetaxel. Bands can be observed at 1006, 1605, 1715 and 3072 cm\(^{-1}\) of SLN-DTX spectra, and these are not observed in blank-SLN spectra. These bands are attributed to the vibrational modes \(\nu_{C=C}(\text{aromatic})\), \(\nu_{C=C}\) with \(\nu_{C=O}\), \(\nu_{C=O}\) of the carbonyl groups and \(\nu_{(O-H)}\). The presence of these DTX characteristic bands, even at a low intensity, permits us to infer that the drug is present in the lipid system (SLN-DTX).

Some peaks observed in DTX spectra decreased or are absent in SLN-DTX Raman spectra, which indicates that the crystalline structure of the drug was lost after incorporation into the carrier. The same was observed by Gao et al. [41], in a study which incorporated DTX into albumin-lipid nanoparticles, in which some DTX bands had reduced intensity or disappeared after incorporation into the nanoparticles.

**Differential scanning calorimetry—(DSC)**

Differential scanning calorimetry is generally used to obtain information about physical and energy properties of a compound or formulation. Based on physical or chemical sample changes, the DSC technique measures...
Table 1 DSC of solid lipid nanoparticle constituents and docetaxel

| Sample     | $T_{\text{peak}} / ^\circ C$ | $\Delta H (J/g)$ |
|------------|-------------------------------|-----------------|
| Compritol  | 73.50                         | 95.05           |
| Pluronic   | 57.51                         | 133.05          |
| Span 80    | 129                           | 34.60           |
| Docetaxel  | 168.1                         | 7.92            |

the loss or gain of heat in samples as a function of temperature [42]. Thermograms of DTX, Compritol, Pluronic F127, Span 80, blank-SLN and SLN-DTX are shown in Fig. 3-c. The thermal data (melting point and $\Delta H$) of the SLNs and DTX constituents are shown in Table 1.

Thermal analysis of Compritol 888 ATO by DSC showed 73.5 °C as the endothermic peak, corresponding to the melting point of the compound in polymorph form β, the most stable form [17]. Rahman et al. [23], showed that the melting point of Compritol 888 ATO was also observed at 71.2 °C, indicating the crystalline nature of polymorph β. The presence of the endothermic melting peak of Compritol at 69 to 74 °C confirmed the solid state of the lipid core within Blank-SLN and SLN-DTX. The crystalline state of the lipid core is essential for the incorporation of the lipophilic drug and the sustained release properties of the lipid nanoparticles [34]. Pluronic F127 shows an endothermic peak that corresponds to melting at 57.51 °C, and a similar result was observed by Newa et al. [43] and Karolewicz et al. [18]. Indeed, the authors reported the Pluronic F127 endothermic event at 57.29 °C and 53.42 °C, respectively. Span 80 at room temperature (initial analysis temperature) is liquid and it is not possible to visualize the melting point in DSC. Initial Span 80 degradation is at 129 °C [19].

DSC curve of DTX shows an endothermic peak at 168.1 °C, corresponding to the drug’s melting point [44]. This endothermic peak of DTX were no longer present in DSC thermogram of SLN-DTX. This would suggest the prevalence of strong drug–lipid interactions, with the conversion of initially crystalline DTX into an amorphous state or disordered in lipid core [8, 45]. The absence of the characteristic DTX peaks in DSC was previously shown to be related to the loss of DTX crystallinity [8, 46]. Sanna et al. [47] studied polymeric particles containing DTX for prostate cancer treatment. In all nanoparticles analyzed, the authors observed that the DTX melting peak disappeared completely from the DSC curve, evidencing the absence of a crystalline drug in nanoparticle samples. Data from other previous studies also demonstrate that it is not possible to observe the peaks related to DTX fusion in the DSC curve of the nanoparticle formulation containing the drug [7, 45, 48–50]. Moreover, the slower release of DTX from SLN-DTX, as shown in the results of the in vitro study, may also be attributed to the strong DTX–lipid interaction.

In vitro cytotoxicity studies—MTT assay

To evaluate the cytotoxicity of SLN-DTX and free DTX, the MTT assay was performed using breast cancer cell lines (4T1 and MCF7) and non-cancerous cells (NIH-3T3 and HNTMCs). The results were compared with that of a clinically available DTX formulation, and the cytotoxicity of Blank-SLN was also investigated to exclude any non-specific effect. Cells were treated at 0.001, 0.01, 0.1, 1, 10 and 100 µg/mL equivalent DTX concentrations for 24 h (Figs. 4 and 5a, c) and 48 h (Figs. 4 and 5b, d). Blank-SLN had no effects on the cell viability and showed a similar result to the non-treated cells. It can be inferred that the blank-SLN composition is biocompatible and suitable for usage in intracellular applications.

The IC$_{50}$ values of SLN-DTX against 4T1 cells were found to be 0.08 µg/mL (24 h) and 0.01 µg/mL (48 h) and for free DTX were 10 µg/mL (24 h) and 0.3 µg/mL (48 h), indicating time and dose-dependent cytotoxicity (Fig. 4a, b). The data of MCF7 cells demonstrate that the IC$_{50}$ values of SLN-DTX were 1.04 µg/mL (24 h) and 0.05 µg/mL (48 h) and for free DTX were 12.19 µg/mL (24 h) and 10.01 µg/mL (48 h) (Fig. 5a, b). SLN-DTX showed higher cytotoxicity against cancer cells, while free DTX was toxic for both human and murine non-cancerous cells (HNTMCs and NIH-3T3). SLN-DTX demonstrated a significantly reduced IC$_{50}$ value (p < 0.0001), which was found to be more than 100 times lower in concentration than free DTX, after 24 h of treatment, indicating higher cytotoxicity and efficiency of nanoparticles. Thus, it was concluded that the SLN-DTX was more effective, according to the release study, since a lower drug amount was released (69.4 µg/mL) in 24 h, compared to the free DTX that released 1000 µg/mL at the same time, and resulted in cytotoxic effects comparable. These results are in agreement with previous studies that showed that the cytotoxicity of drug-loaded lipid-based nanoparticles was higher than that of free drugs [4, 34, 47, 51, 52]. The enhanced efficacy mechanism of SLN-DTX cytotoxicity could be due to its rapid absorption and high permeability, which permit the intracellular nanoparticles to accumulate, mediated by endocytosis [2, 16], as shown in our TEM (internalization) and uptake results.

4T1 morphology

Phase contrast and scanning electron microscopy observations illustrated that the treated and untreated cells have morphological differences. These differences were observed with both techniques used (Fig. 6). The control cells showed a smooth cellular surface with characteristic...
cytoplasmic projections in most of them, as expected (Fig. 6a). The shape of both cells, after exposure with DTX and SLN-DTX treatments, was altered, the cytoplasmic projections decreased. Previous studies have shown similar results [53, 54]. These morphological surface alterations may be related to the disruption in the cytoskeleton dynamics promoted by DTX [55]. Impairment in the microtubule remodeling, induced by DTX, can affect cell surface morphology.

**Cell cycle analysis and cell apoptosis**

Cell cycle deregulation is one of the hallmarks of cancer cells. Therefore, the induction of cell cycle arrest may be a good and effective strategy to control aberrant cancer cell proliferation [56]. Docetaxel has been shown to induce microtubule damage, which results in prolonged G2-M arrest and subsequent apoptosis [57]. Cell cycle analysis of 4T1 cells exposed to SLN-DTX or DTX is shown in Fig. 7-a. Consistent with previous results [57–59], cells treated with SLN-DTX or DTX resulted in an arrest in the phase of G2-M, with a significant decrease in G0/G1 phase versus control cells. The accumulation in G2-M phase was significantly higher in cells treated with SLN-DTX (73.7%) than in cells treated with free DTX (67.8%), suggesting that DTX was released into the cytosol, which caused cell cycle arrest in the G2-M phase. These results are consistent with the data obtained by MTT analysis and provide further evidence for potential clinical applications of SLN-DTX.

Apoptosis is considered the main cell death mechanism in response to taxanes. Apoptosis occurs when cells externalize a lipid found on the inner surface of the cell membrane, phosphatidylserine, which can be labeled with fluorochrome-conjugated annexin V. Generally, viable cells that have intact membranes do not interact with propidium iodide (PI), while membranes of dead cells are permeable to PI [60]. It is possible to differentiate viable cells (stained negative for both annexin V-FITC and propidium iodide), early apoptosis (stained positive for annexin V-FITC and negative for PI), late apoptosis (stained positive for both annexin V-FITC and PI), and necrosis (stained positive for PI) [59]. Apoptotic cells show changes at the morphological and biochemical level, such as nuclear cytoplasmic condensation and chromatin aggregation. On the other hand, necrosis shows a passive consequence of gross injury to the cell
with physiological consequences that are very different from apoptosis. In necrosis, the cell’s ability to maintain homeostasis is impaired [61]. Early apoptosis is represented by the cells accumulating in the lower right quadrant of the dot plot drawn between Annexin V-FITC and propidium iodide. As shown in Fig. 7b, the early and late apoptotic rates in the control group were 5.5% and 1.5%, respectively. Early apoptotic cells in the presence of SLN-DTX exhibited a significantly higher rate of 82.5%, as compared to the free DTX, at 67.8%, which could be attributed to the enhanced availability of DTX in SLNs. These results are consistent with the data of cell cycle analysis and suggest that SLN-DTX significantly improved DTX-dependent apoptosis in 4T1 cells in comparison to DTX.

Effects of DTX on microtubules in 4T1 cells

DTX has the ability to induce a cytotoxic effect by binding to the β tubulin subunit [62]. In Fig. 8, untreated cells are shown with clear, organized and extensive microtubule networks. However, cells treated with free DTX and SLN-DTX showed stabilized, shorter and straight microtubules resulting in elongated bundles of microtubules that curved around the cytoplasm, suggesting a change in the regulation of microtubule dynamics from DTX.

Internalization of SLN-DTX by TEM and analysis of cellular uptake

TEM was used to verify the cellular ultrastructure features and uptake of SLN-DTX. Lipid-based nanoparticles, such as SLNs, have been widely used as pharmaceutical carriers to increase the efficacy of chemotherapeutics [63]. Previous studies have demonstrated the internalization of lipid nanoparticles by endocytic pathway in various cell types [63, 64]. Consistent with the manner of internalization, the endocytosed nanoparticles were mainly accumulated within lysosomes/and or endosomes in the cytosol of the cell (Fig. 9a III–VI). Some of the nanoparticles appear to be digested within the vesicles. It appears that nanoparticles are arranged in clusters and individual particles can still be recognized (Fig. 9a III–VI). The nucleus can be identified, and the images consistently indicate that SLN-DTX were not present in the nucleus (Fig. 9a III). The control cells can be observed in Fig. 9a I–II.
To evaluate cellular uptake efficiency, in 4T1 cells, the DTX intracellular accumulation was analyzed by HPLC method. Cellular uptake was performed for SLN-DTX compared with free DTX. Results showed that DTX uptake from SLN-DTX by the cell was significantly higher at periods of 4 h, 18 h and 24 h than for free DTX. The DTX uptake accumulation is time-dependent, increasing over time, in cells treated with SLN-DTX. Otherwise, cells treated with free DTX have accumulation maintained up to 4 h and then DTX concentration decays (Fig. 9b). Mosallaei et al. [8] showed that TXT from the uptake of solid lipid nanoparticles in C-26 cells is greater when compared to the free TXT. These findings suggest that the use of SLN-DTX may allow doses of DTX to be decreased without loss of therapeutic effect, thereby reducing the drug’s toxicity.

In vivo antitumor efficacy
The in vivo therapeutic performances of SLN-DTX and free DTX were studied in 4T1 tumor-bearing Balb/c mice at 10 mg/kg DTX for a total of five doses. The dose was selected based on the previous works in literature [8, 44, 65]. In agreement with the in vitro cytotoxicity data, the group treated with SLN-DTX showed the lowest tumor growth rate (Fig. 10a). The results of tumor volume showed that the tumors of mice in the PBS and Blank-SLN groups grew rapidly, but the tumors in the docetaxel and SLN-DTX groups grew slowly. Treatments with docetaxel inhibited the tumor growth by about 42.7%, and SLN-DTX by 92.7% at the end point of study, which was significantly smaller than that in the PBS group. A previous report [16] showed tumor regression of mice treated with encapsulated DTX (10 mg/kg) was more effective than free DTX, which corroborated our findings.

There was no statistically significant variation in mice weight between the groups during the study, showing the negligible systemic toxicity of different treatments with the given dose (Fig. 10b). There were also no significant differences in the hematological and biochemical parameters (Additional file 6: Table S3).

Lung metastasis prevention and IL-6 serum level of 4T1 breast cancer
We studied prevention of spontaneous metastasis in lung by SLN-DTX treatment. Spontaneous metastasis usually
occurs in late stages of cancer, and the metastasis of 4T1 breast cancer occurs primarily in the lungs, sharing many characteristics with human breast cancer [66].

In PBS and Blank-SLN groups, we could clearly see many metastatic nodules about the lungs (Fig. 11a). After treatment with DTX, metastatic nodules were slightly reduced. In contrast, there was no metastasis in the SLN-DTX group, suggesting that SLN-DTX could significantly inhibit 4T1 breast cancer metastasis to the lung, also decreasing numbers of tumor nodules, and the size of tumor nodules (Fig. 11b). The metastasis was further confirmed by H&E staining analysis. As shown in Fig. 11c, many tumor metastasis loci (red dotted circle) were observed in lungs of PBS and Blank-SLN groups and a moderate number in lungs of docetaxel group, while there was no metastasis in the lungs of SLN-DTX group. These results suggest that SLN-DTX has a greater ability to inhibit tumor metastasis to lungs than free docetaxel.

Unbalanced cell proliferation is correlated with tumor progression, evasion from immune response and metastatic potential. These changes are associated with alteration in the production of cytokines [67]. Interleukin-6 (IL-6) is a pleiotropic cytokine that functions in the regulation of pro-inflammatory and metastatic tumor. Studies have shown increased circulating levels of IL-6 in patients with breast cancer. High IL-6 levels are also associated with cancer development, progression and metastasis [67, 68]. In addition, a previous study reported that breast tumor-bearing mice expressing high levels of IL-6 had spontaneous lung and liver metastasis [69]. Therefore, we evaluated IL-6 serum levels in mice after treatments.

In our results, IL-6 levels were significantly higher in groups with presence of metastatic disease in lungs (as shown in H&E and lung metastasis results) that is the PBS, Blank-SLN and DTX (628 ± 3.4; 568 ± 1.7; 345 ± 6.6 pg/mL; p < 0.0001) groups, when compared with the healthy control group. There was no significant difference between the healthy control group and the SLN-DTX treated group (Fig. 11d). These findings...
support the important role of IL-6 levels in breast cancer invasion and metastasis. In studies carried out by Salgado et al. [67] high IL-6 serum levels were shown to be associated with lower survival in patients with advanced breast cancer and, at later stages, high levels may stimulate tumor growth.

**Bcl-2 and Ki-67 immunohistochemistry analysis**

Bcl-2 is a proto-oncogene related with programmed cell death/apoptosis. Studies have shown the overexpression of Bcl-2 protein increase invasion and migration in breast cancer [70, 71]. In this context, based on results we found regarding metastasis prevention by SLN-DTX treatment, we investigated Bcl-2 in lungs and tumor tissues by immunohistochemistry (Fig. 12). Strong staining of Bcl-2 was observed in groups previously identified with pulmonary metastasis, that is, the PBS, Blank-SLN and DTX groups, when compared to SLN-DTX group, which showed statistically significant differences (Fig. 12c, f) (p**** < 0.0001).

We performed Ki-67 to examine cell proliferation in the tumors and lungs after treatments and control groups. The analysis revealed high positive indexes of PBS, Blank-SLN and DTX groups. The SLN-DTX treatment induces significantly lower (****p < 0.0001) levels of cellular proliferation in comparison with control PBS group (Fig. 12b, e). Therefore, these results suggested that SLN-DTX induced the reduction of cell proliferation and that it is associated with tumor growth suppression, as observed previously.

**Conclusions**

SLN-DTX was successfully prepared using the high-energy method. The results showed that SLN-DTX is stable over time, with uniform distribution and high encapsulation efficiency (86%). The in vitro release study showed a sustained and continuous release pattern of SLN-DTX. The amorphous state of DTX in SLN-DTX was confirmed by DSC. The in vitro tests proved that SLN-DTX has higher cytotoxicity against tumor cells, an efficient cellular uptake
and arrested cell cycle progression in the G2/M stage; it also induced more apoptosis in 4T1 cells at a lower dose compared with DTX. SLN-DTX was taken up by the 4T1 cells through an endocytosis process, localized mostly in the lysosomes. In vivo study indicated that SLN-DTX not only significantly inhibited the tumor growth of 4T1 breast

![Image](image_url)

**Fig. 9** a Ultrastructural images of 4T1 cells. (I–II) Control cells (untreated). (III–VI) Cells treated with 10 µg/mL of SLN-DTX for 24 h. (III–V) SLN-DTX internalized (dashed line); (V) cluster of SLN-DTX in cytoplasm (dashed line); (VI) internalization of SLN-DTX into lysosomes (arrows). Dashed lines, arrows (into lysosomes) and arrow heads indicate nanoparticles. ER Endoplasmic reticulum, M Mitochondria. Magnification: 5 K, 15 K (black dashed lines). b In vitro cellular uptake studies of DTX in 4T1 cells. Cells were exposed to SLN-DTX or DTX for 1 h, 4 h, 18 h and 24 h at 100 µg/mL. Data are expressed as mean ± standard error of the mean (****p < 0.0001)

![Image](image_url)

**Fig. 10** Antitumoral effect of SLN-DTX, Docetaxel, Blank-SLN and PBS on 4T1 tumor-bearing Balb/c mice. a Variation of tumor volume and b mice weight. ***p < 0.001; ****p < 0.0001, compared with PBS group
cancer, but also prevented lung metastasis at a dose of 10 mg/kg that did not cause noticeable systemic toxicity in mice. Our findings suggest that SLN-DTX inhibits tumor growth and prevents lung metastasis by reducing the production of IL-6 serum level, inducing apoptosis of the tumor cells and reduction of tumor cell proliferation and BCL-2 expression. In conclusion, these results endorse the proposal that SLN-DTX can be considered as an alternative and promising biocompatible formulation to be used for the treatment of breast cancer.

**Materials**

Docetaxel, MTT, Annexin, Propidium iodide, Pluronic F127, Span 80 and Compritol ATO 888 were purchased from Sigma. Mouse mammary cell line (4T1), human breast cancer cells (MCF7) and mouse embryo fibroblast cell line (NIH-3T3) were acquired from the Rio de Janeiro Cell Bank. Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park Memorial Institute medium 1640 (RPMI) medium, fetal bovine serum (FBS), penicillin and streptomycin were bought from Gibco, Invitrogen. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium-bromide) came from Thermo Fisher; osmium tetroxide from Electron Microscopy Sciences, Hatfield, PA; and acetonitrile (99.95%—grade HPLC) from J.T. Backer. All other chemicals were of analytical grade.

**Methods**

**Preparation of solid lipid nanoparticles (SLNs)**

Blank-SLN (without docetaxel) or SLN-DTX were prepared by the high-energy method. In brief, aqueous and oil phases were prepared separately. The oil phase of Compritol (500 mg), Span 80 (50 mg) and Pluronic F127 (450 mg) was melted and kept at 80 °C and then DTX (20 mg) was added to oil phase until it melted completely. The aqueous phase (20 mL of PBS) was added dropwise to the oil phase at the same temperature (80 °C) by continuous high-speed stirring using Ultra-Turrax T25 (IKA-Werke, Saufen, Germany) at 10,000 rpm for 10 min. The final status of the products, is it dispersed in PBS.

**Determination of hydrodynamic diameter (HD), polydispersity index (PDI) and zeta potential**

The physicochemical parameters including hydrodynamic diameter, PDI and zeta potential of SLN-DTX were recorded over the period of 120 days by dynamic light scattering (DLS) using Zeta Sizer (Nano ZS, Malvern Instruments, UK) at 25 °C. All measurements were carried out after dilution (1:20) with distilled water.

In order to evaluate the storage stability, SLN-DTX was stored at 4 °C, and after 24 h was withdrawn and analyzed for mean hydrodynamic diameter, PDI and zeta potential.
Fig. 12 Immunohistochemistry analysis. The brown dye-stained cells represent positive cells. a Lung and d tumor slides were immunostained with anti-Ki-67 and BCL-2. b, e Quantification of Ki-67 and c, f BCL-2 staining. Data represent mean values ± standard error (**p < 0.01; ***p < 0.001; ****p < 0.0001)
by DLS. Then, the same sample was stored at 37 °C for 24 h and the measurement was performed, so on until completing 5 total readings. The same parameters were measured after the end of each cycle.

Interaction between SLN-DTX and biological media were performed with sample dilution (1:20) in distilled water, PBS, cell media (10% v/v in PBS) and serum (10% v/v in PBS). DLS was used to record hydrodynamic diameter, PDI and zeta potential up to 7 days after formulation.

Transmission electron microscopy
The size and morphology of SLN-DTX were characterized using transmission electron microscope—TEM (JEOL 1011, Tokyo, Japan) operated at accelerating voltage of 100 kV. Samples were prepared by placing a drop of sample (5 µL) using a 400-mesh copper grid coated with Formvar film, and then it was air-dried, following contrast enhancement with osmium tetroxide vapor. Grids were kept at room temperature until analysis. A minimum of 400 particles were measured using ImageJ software.

Quantification of DTX by high performance liquid chromatography (HPLC)
DTX concentration was analyzed by HPLC (Shimadzu, Kyoto, Japan). The stationary phase consisted of a reversed phase ACE AQ C18 column (25 × 0.4 cm, 5 µm particle diameter) (ACE Aberdeen, Scotland) with a precolumn (1 × 0.4 cm, 5 µm particle diameter) (ACE Aberdeen, Scotland). The column temperature was maintained at room temperature. The mobile phase consisted of acetonitrile/deionized water (55:45, v/v). The injection volume was 20 µL, the flow rate was 1 mL/min at a pressure of 120 kgf/cm². The temperature of the column was maintained at 30 °C during all the runs. UV detection was performed at a wavelength of 232 nm. A calibration curve (y = 21752x − 128538, R² = 0.9994) was drawn using different concentrations of DTX with a range of 0.01–1 mg/mL.

In vitro drug release study
The determination of the drug release behavior from SLN-DTX was performed by the dialysis bag (14 kDa Sigma, USA) method. Phosphate-buffer saline (PBS, pH 7.4 or pH 5.0) containing 0.1% Tween-80 was used as the release medium. The bag containing SLN-DTX (1 mg/mL of DTX) was incubated in 50 mL release medium at 37 ± 0.5 °C under horizontal shaking speed of 100 rpm. Samples at specified time intervals (0, 0.25, 0.5, 1, 2, 4, 6, 24, 48, 72, 120 and 240 h) were withdrawn and replaced immediately with the same volume of fresh release medium. The released DTX content was determined by HPLC.

Determination of encapsulation efficiency and drug loading of SLN-DTX
SLN-DTX (formulation dispersed in PBS) in was submitted to centrifugation at 3000 rpm for 10 min and then the supernatant was collected, diluted 1:10 (v/v) in DMSO and submitted to the ultrasonic bath for 5 min to promote separation of the DTX from the others lipid components. This mixture was then diluted (1:100, v/v) in the mobile phase that consisted of acetonitrile and deionized water with a ratio of 55:45 (v/v), submitted to gentle centrifugation of 2500 rpm at 5 min, to promote sedimentation of residual lipids, then analysis by HPLC under the conditions mentioned in the above item (Quantification of DTX by high performance liquid chromatography (HPLC)). The entrapment efficiency (EE%) and drug loading (DL%) were calculated by the following formulas:

\[
\text{Entrapment efficiency (EE%)} = \frac{\text{weight of DTX in SLNs}}{\text{weight of DTX used in SLNs preparation}} \times 100 \tag{1}
\]

\[
\text{Drug loading (DL%)} = \frac{\text{weight of DTX in SLNs}}{\text{Weight of SLNs}} \times 100 \tag{2}
\]

Fourier transform infrared spectroscopy (FTIR)
The changes within the functional groups of the samples were observed using Fourier transform-infrared spectroscopy (Vertex 70, Bruker, Billerica, USA). FTIR spectrum of DTX, Compritol ATO 888, Span 80, Pluronic F127, SLN-DTX and Blank-SLN were obtained by ATR (attenuated total reflectance) method. FTIR spectra were measured over the range of 4000–400 cm⁻¹ with resolution of at 4 cm⁻¹ for 50 scans.

Differential scanning calorimetry (DSC)
Thermograms of Compritol ATO 888, Span 80, Pluronic F127, DTX, SLN-DTX and Blank-SLN were obtained by using differential scanning calorimetry DSC-60 (Shimadzu, Kyoto, Japan). DTX in dry powder format and the other samples in liquid form. Samples were weighed, a mass of 4.4 mg, 22 mg, 12.3 mg, 3.2 mg, 2.6 mg, 9.5 mg of Compritol ATO 888, Span 80, Pluronic F127, DTX, SLN-DTX and Blank-SLN, respectively, in DSC aluminum crimped pans, and an empty pan was used as reference. DSC was performed at 25–400 °C temperature range at the rate of 10 °C/min under N₂ flow to provide inert atmosphere during the measurement to prevent oxidation reaction.
Confocal raman microscopy (CRM)
SLN-DTX, Blank-SLN, Compritol ATO 888, Span 80 and Pluronic F127 spectroscopic analyses were performed by a confocal Raman spectrometer (Witec GmbH, Germany) with a 532 nm laser at 30 mW. The spectra were recorded at an integration time of 0.15 s per point.

Cell culture
Murine breast adenocarcinoma cells (4T1), human breast cancer cells (MCF7) and murine embryo fibroblast (NIH-3T3) cells were cultured in RPMI-1640 or DMEM, supplemented with 10% fetal bovine serum (v:v), penicillin (100 U/mL), and streptomycin (100 U/mL), at 37 °C in a humidified atmosphere containing 5% CO2. Primary cultures of Human non-tumor mesenchymal cells (HNTMCs), provided informed consent and with approval from the human ethics committee of the University of Brasilia (104934/2008). HNTMCs were cultured in DMEM. Cells in the logarithmic growth phase were used in the following cell experiments. NIH3-3T3 and HNTMCs were used as non-tumor control cells.

Cell viability assay
The cytotoxicity was determined by colorimetric-based MTT assay. Cells were seeded in a 96-well plate at a density of 4 × 10^3 cells/well and incubated overnight. Then, each well was replaced with fresh medium containing different doses of DTX, Blank-SLN, SLN-DTX, or culture medium (negative control) for 24 or 48 h culture. Subsequently, the culture medium was replaced with one containing MTT (5 mg/mL), and cells were incubated for 4 h at 37 °C. Then, the supernatant was dropped and DMSO was added to each well to dissolve the formazan crystals. Absorbance was measured at 595 nm. Untreated cells were taken as control with 100% viability. The drug concentration at which the growth of 50% cells was inhibited (IC50) in comparison with that of the control sample was calculated by curve fitting of the cell viability data. All experiments were performed in triplicate.

Cell morphology
The morphology and confluence of 4T1 cells were analyzed using a phase contrast microscope (Zeiss, Germany) and the AxioVision® software (Zeiss, Germany).

Twenty-four hours after treatment (10 µg/mL), 4T1 cells were fixed with Karnovsky overnight. Samples were washed with cacodylate buffer (0.1 M), post-fixed with osmium tetroxide and dehydrated using graded acetone (30–100%). Then, they were critical-point-dried (Balzers, CPD 030, Germany) from liquid CO2 and gold-sputtered. The cell morphology was observed using scanning electron microscopy.

Cell cycle
Cell cycle analysis was carried out by staining the DNA at different stages with propidium iodide (PI), determined by flow cytometry. Briefly, 1 × 10^5 cell/well were seeded in 24-well cell culture plates. The 4T1 cells were exposed to SLN-DTX or DTX treatment (10 µg/mL) for 24 h. Cells were washed with PBS and trypsinized, then harvested and centrifuged. The pellet was washed in PBS, fixed in ice-cold ethanol (70%) at 4 °C. Then, cells were stained with propidium iodide solution consisting of 45 mg/mL PI, 10 mg/mL RNase A, and 0.1% Triton X-100. After 1 h of incubation at 37 °C in a CO2 incubator, flow cytometry analysis was performed using FACS-Calibur (BD Biosciences Co., Franklin Lakes, New Jersey, USA). The data were analyzed using FlowJo single cell analysis software.

Cell apoptosis analysis
Annexin-V staining was performed to differentiate apoptosis from necrotic cell death induced by SLN-DTX or DTX. The same dose that had been applied to the cells and the same incubation time as in cell cycle analysis were used. The cells were then harvested, washed with cold PBS and centrifuged. The cell pellet was resuspended in annexin-binding buffer, and then Annexin V FITC conjugate and propidium iodide solution were sequentially added to the sample in order to detect apoptotic and necrotic cell populations, respectively. Finally, the cells were incubated at room temperature for 15 min and measurement was conducted by flow cytometer. A total of 20,000 events were collected per sample.

Immunocytochemical staining
4T1 cells were cultured in twelve-well plates with cover glass for 24 h and then treated with SLN-DTX or DTX (10 µg/mL). Normal culture medium was used as a control. After 24 h of incubation, the cells were fixed with 4% paraformaldehyde for 15 min. The cells were washed with PBS and permeabilized with 0.5% Triton X-100 for 10 min. The cells were stained with a primary antibody against tubulin at a dilution of 1:500 at 4 °C overnight. A FITC-conjugated goat anti-rabbit IgG was used to combine the tubulin antibody. The nucleus was stained with DAPI (0.1 µg/mL) for 7 min and the cover slips were mounted on glass slides. The cells were analyzed with a Zeiss Axiophot microscope (Carl Zeiss, Jena, Germany).

In vitro cellular uptake
The cellular uptake of DTX by 4T1 cells was analyzed quantitatively, performed by analytical method of HPLC. The cells (10^5 cells/well) were seeded in 24-well plates. Cells were treated with SLN-DTX or DTX (100 µg/mL) for 1, 4, 18, and 24 h at 37 °C under 5% CO2. At the end of
the incubation period, cells were washed three times with ice-cooled PBS to remove any SLN-DTX or DTX that remained in the surrounding matrix or on the cell membrane surface. Cells were trypsinized for 15 min until all the cells were detached; 800 µL methanol was added to each well and it was shaken for 3 min. After that, each sample was kept at 4 °C for 48 h to ensure the destruction of nanoparticle structure and dissolving of all DTX in methanol. Cells were vortexed for 1 min, and centrifuged for 10 min at 1000g at 4 °C. The supernatant was kept and analyzed by HPLC method in the same way as mentioned previously in “Quantification of DTX by high performance liquid chromatography (HPLC)” section.

Internalization of SLN-DTX in 4T1 cells
Briefly, 4T1 cells were seeded (1 × 10^6) and treated with SLN-DTX (10 µg/mL) for 24 h. Then, cells were fixed with Karnovsky fixative and post-fixed with 1% osmium tetroxide containing potassium ferricyanide for 1 h at room temperature. Samples were dehydrated in grading acetone (30–100%) and embedded in Epon resin. Ultrathin sections were stained with 5% uranyl acetate. Ultrastructural studies were performed using a transmission electron microscope (JEOL 1011, Tokyo, Japan) at accelerating voltage 80 kV.

Evaluation of the antitumor activity of the SLN-DTX in vivo
Balb/c female mice (12 weeks old) were purchased from the Catholic University of Brasilia (Brasília, Brazil). All experiments described were approved by the Animal Research Ethics Committee of the University of Brasilia, Brazil. 4T1 cells (4 × 10^5 cells per mouse) were subcutaneously injected into the left flank. The tumors were allowed to grow for 2 weeks. The mice were randomized into five groups with 6 mice in each group; healthy (without tumor), phosphate buffered saline (PBS), Blank-SLN, free DTX and SLN-DTX at a fixed dose of 10 mg/kg. The animals were treated intraperitoneally every 4 days, totaling five applications. The body weights of mice were monitored as an index of systemic toxicity [72]. The tumor size was measured using a digital caliper and calculated using the following formula 4π/3 × (length/2) × (width/2)^2 [51]. On day 28, mice were euthanized, and tumors and lungs were removed. Lungs were fixed in Bouin’s solution and metastatic nodules were counted.

Hematology and blood chemistry tests
Blood samples were collected to carry out hemogram and biochemical dosages. Hemogram was processed in a multiple automated hematology analyzer (XZ 2100 Sysmex equipment) and serum biochemical analyses were run on the automated chemistry analyzer (ADVIA 2400, Siemens).

ELISA
The cytokine IL-6 level was evaluated with an ELISA kit (Sigma, USA) according to the manufacturer’s protocol. Briefly, 100 µL of standard and mice plasma in duplicated wells were incubated at room temperature for 45 min. After washing, 100 µL of enzyme conjugate reagent was added into each well, then incubated. The reaction was stopped and samples were measured with a microplate reader.

Histopathological and immunohistochemical evaluations
The histopathology of tumor and lung sections was evaluated by hematoxylin and eosin (H&E) method. Immunohistochemical evaluation was carried out in Micra laboratory (Brasilia, Brazil). Tissues were embedded in paraffin, sectioned, and stained with an antibody against BCL-2 and Ki-67 (Abcam, Cambridge, MA, USA). Quantification was done in a blind fashion by counting positive cells in 10 fields (400×) using a light microscope (Zeiss, Germany).

Immunohistochemical staining was performed according to the protocol provided by the manufacturer.

Statistical analysis
Statistical evaluation of data was performed using t-test, and one or two-way ANOVA analyses of variance, followed by Tukey’s post-tests using the Graph-Pad Prism 5.0 software. p < 0.05 was considered as the statistically significant difference. Quantitative results were expressed as mean ± standard deviation (SD).

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12951-020-00604-7.
Acknowledgements

The authors acknowledge the Micra Laboratory (Brasilia, Brazil), which performed the immunohistochemistry assay.

Authors’ contributions

SNB, JPLF and EL provided the conceptual framework for the study and made substantial contributions. MCOR was the principal investigator, performed the experiments and wrote the manuscript. PBS conducted the release in vitro, uptake experiments and helped with data analysis. MAR prepared the nanoparticles and contributed with nanoparticles characterization. BYGA helped with in vitro experiments. JVO participated in the in vivo experiments. TV and CM contributed with Raman experiments. All authors read and approved the final manuscript.

Funding

This work was financially supported by the Brazilian agencies: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brazil (CAPES)—Finance Code 001, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Empreendimentos Científicos e Tecnológicos (FINEP), Financiadora de Estudos e Projetos (FINEP) and Fundação de Apoio à Pesquisa no Distrito Federal (FAPDF), all of which are gratefully acknowledged.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Female BALB/c mice were handled in accordance with Committee of the Ethics approval and consent to participate of the University of Brasilia (Brasilia, Brazil) Project Number 66726/2016.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interests.

Author details

1 Electron Microscopy Laboratory, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil. 2 Nanobiotechnology Laboratory, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil. 3 Institute of Medical Physics & Biophysics, Leipzig University, Leipzig, Germany.

Received: 8 September 2019 Accepted: 6 March 2020

Published online: 12 March 2020

References

1. Li Y, Jin M, Shao S, Huang W, Yang F, Chen W, et al. Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model. BMC Cancer. 2014;14:329.

2. Hammadi NI, Abba Y, Hezmee MNM, Razak ISA, Jaji AZ, Isa T, et al. Formulation of a sustained release docetaxel loaded cockle shell-derived nanoparticles: tuning nanostructure and mucoadhesion. AAPS PharmSciTech. 2017;18:1193–203.

3. Zhang H, Wang K, Zhang P, He W, Song A, Luan Y. Redox-sensitive micelles assembled from amphiphilic mPEG-PCL-SS-DTX conjugates for the delivery of docetaxel. Colloids Surf B Biointerfaces. 2016. https://doi.org/10.1016/j.colsurfb.2016.02.045.

4. Wang L, Liu Z, Liu D, Liu C, Juan Z, Zhang N. Docetaxel-loaded-lipid-based-nanoparticles (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm. 2011;413:194–201. https://doi.org/10.1016/j.ijpharm.2011.04.023.

5. Cho H, Yoon I. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel enhanced intestinal absorption and lymphatic uptake. Int J Nanomed. 2014;9:495–504.

6. Piccart-Gebhart MJ, Burzoykovski T, Buyse M, Sledge G, Carmichael J, Luck HJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26:1980–9.

7. Fang G, Tang B, Chao Y, Xu H, Gou J, Zhang Y, et al. Cysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: a permeability and pharmacokinetic study. Mol Pharm. 2015;12:3384–95.

8. Mosallaei N, Jaafari MR, Hanafi-Bidj M, Golmohammadsadagh S, Malekhe-Nikouei B. Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations. Pharm Nanotechnol. 2013;9:340–7.

9. Immodimo ML, Brusa P, Arpicco S, Stella B, Bosio F, Catell L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release. 2003;91:417–29.

10. Li X, Du L, Wang C, Liu Y, Mei X, Jin Y. Highly efficient and lowly toxic docetaxel nanoemulsions for intravenous injection to animals. Pharmazie. 2011;66:479–83.

11. Yang M, Ding Y, Zhang L, Qian X, Jiang X, Liu B. Novel thermosensitive polymeric micelles for docetaxel delivery. J Biomed Mater Res Part A. 2007;81:847–57.

12. Sandri G, Motta S, Bonferroni MC, Brocca P, Rossi S, Ferrari F, et al. Chitosan-coupled solid lipid nanoparticles: tuning nanostructure and mucoadhesion. Eur J Pharm Biopharm. 2017;110:113–8. https://doi.org/10.1016/j.ejpb.2016.10.010.

13. Zhang L, Zhang N. How nanotechnology can enhance docetaxel therapy. Int J Nanomed. 2013;8:2927–41. https://doi.org/10.2147/ijn.s46921.

14. Cho JBC. Comparison of solid lipid nanoparticles for encapsulating paclitaxel or docetaxel. J Pharm Invest. 2015;45:625–31.

15. Bhatlekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech. 2009;10:289–96.

16. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces. 2011;85:262–9. https://doi.org/10.1016/j.colsurfb.2011.02.038.

17. Aburajma MH, Badi-Eldin SM. Compitol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals. Expert Opin Drug Deliv. 2014;11:1865–83.

18. Karolewicz B, Gajda M, Pluta J, Gorniak A. The effect of Pluronic F127 on the physicochemical properties and dissolution profile of lovastatin solid dispersions. J Therm Anal Calorim. 2016;123:2283–90.

19. Fu X, Kong W, Zhang Y, Jiang L, Wang J, Lei J. Novel solid-solid phase change materials with biodegradable trihydroxy surfactants for thermal energy storage. RSC Adv. 2015;5:68881–9.

20. Helgason T, Awad TS, Kirksbergson K, Mcclemens DJ, Weiss J. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). J Colloid Interface Sci. 2009;334:75–81. https://doi.org/10.1016/j.jcis.2009.03.012.

21. Pawar VK, Gupta S, Singh Y, Meher JG, Sharma K, Singh P, et al. Pluronic F-127 stabilised docetaxel nanocrystals improve apoptosis by mitochondrial depolarization in breast cancer cells: pharmacokinetics and toxicity assessment. J Biomed Nanotechnol. 2015;11:1747–63.

22. Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 2013;334:157–75.

23. Rahman Z, Zidan AS, Khan MA. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm. 2010;76:127–37. https://doi.org/10.1016/j.ejpb.2010.05.003.

24. Schwarz C, Mehmert W. Solid lipid nanoparticles (SLN) for controlled drug delivery: II. Drug incorporation and physicochemical characterization. J Microencapsul. 1999;16:205–13.

25. Alewis F, Pridgen E, Molnar LX, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–15.

26. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941.

27. Moore TL, Rodriguez-Lorenzo L, Hirsch V, Balog S, Urban D, Jud C, et al. Nanoparticle colloidal stability in cell culture media and impact on cellular interactions. Chem Soc Rev. 2015;44:6287–305.

28. Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles faces. 2011;85:262–9. https://doi.org/10.1016/j.colsurfb.2011.02.038.

29. Estella-Hermoso de Mendoza A, Rayo M, Mollinedo F, Blanco-Prieto MJ. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation, development and in vivo characterization. Eur J Pharm Biopharm. 2008;66:207–13.
30. Semete B, Booyens LJ, Kalombo L, Venter JD, Katara L, Ramalapa B, et al. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol Appl Pharmacol. 2010;249:158–65.

31. Liu Y, Pan J, Feng SS. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm. 2010;395:243–50.

32. Jansook P, Pichayakorn W, Rithidej GC. Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): effect of drug loading and biopharmaceutical characterizations. Drug Dev Ind Pharm. 2018;44:1693–700.

33. Shafique M, Khan MA, Khan WS, Maqsood-Ur-Rehman, Ahmad W, Khan S. Fabrication, characterization, and in vivo evaluation of farnomolide loaded solid lipid nanoparticles for boosting oral bioavailability. J Nanomater. 2017. https://doi.org/10.1155/2017/357150.

34. Qureshi OS, Kim HS, Zeb A, Choi JS, Kim HS, Kwon JE, et al. Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration. J Microencapsul. 2013;30:43–61. https://doi.org/10.3109/02652048.2017.1337247.

35. Albano JM, de Ribeiro LN, Couto VM, Barbosa Messias M, Rodrigues da Silva GH, Breitkreitz MC, et al. Rational design of polymer-lipid nanoparticles for docetaxel delivery. Colloids Surf B Biointerfaces. 2019;175:56–64.

36. Krishnamurthi P, Ramaligam HB, Raju K. FTIR studies of hydrogen bonding interaction between the hydroxy and carbonyl liquids. Adv Appl Sci. 2015;6:44–52.

37. Stuart BH. Infrared spectroscopy: fundamentals and applications. Hoboken: Wiley; 2005.

38. Jain A, Thakur K, Kush P, Jain UK. Docetaxel loaded chitosan nanoparticles: formulation, characterization and cytotoxicity studies. Int J Biol Macro. 2011;69:546–53.

39. Cipriani P, Ben-amotz D. Characterization of select members of the Taxane family using Raman spectroscopy. J Raman Spectrosc. 2005;36:1052–8.

40. Loiseau A, Boudon J, Mirjpeet C, Chêrange G, Millot N. Taxane-grafted metal-oxide nanoparticles as a new theranostic tool against cancer: the promising example of docetaxel-functionalized tritate nanoparticles on prostate tumors. Adv Healthc Mater. 2017;6:1–10.

41. Gao H, Cao S, Yang Z, Zhang S, Zhang Q, Jiang X. Preparation, characterization and anti-glioma effects of docetaxel-incorporated albumin-lipid nanoparticles. J Biomed Nanotechnol. 2015;11:2137–47.

42. Wang T, Zhu D, Liu G, Tao W, Cao W, Zhang L, et al. Docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30:226–32. https://doi.org/10.1016/j.biomaterials.2008.09.014.

43. Wang H, Li L, Wang P, Wang X, Zhang K, Liu Q. Comparison of photodynamic treatment produced cell damage between human breast cancer cell MCF-7 and its multidrug resistance cell. Photodiagn Photodyn Ther. 2016;16:1–8.

44. Hammami NI, Abba Y, Hezemee MNM, Razak ISA, Kura AU, Zakaria ZAB. Evaluation of in vitro efficacy of docetaxel-loaded calcium carbonate aragonite nanoparticles (DTX-CaCO3NP) on 4T1 mouse breast cancer cell line. In Vitro Cell Dev Biol Anim. 2017;53:896–907.

45. Hermenean A, Ardelean A. Targeting the cytoskeleton with plant-bioactive compounds in cancer therapy. Cytoskelet Struct Dyn Funct Dis. 2017.

46. Zhao X, Qi T, Kong C, Hao M, Wang Y, Li J, et al. Photothermal exposure of polydoxorubicin-coated branched Au−Ag nanoparticles induces cell cycle arrest, apoptosis, and autophagy in human bladder cancer cells. Int J Nanomed. 2018;13:6413.

47. Wang T, Zhu D, Liu G, Tao W, Cao W, Zhang L, et al. Docetaxel-loaded star-shaped TAPPA-PLA-b-TPGS nanoparticles for cancer chemical and photodynamic combination therapy. RSC Adv. 2015;5:50617–27.

48. Luo Y, Ling Y, Guo W, Pang J, Liu W, Fang Y, et al. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release. 2010;147:728–88.

49. Hernández-Vargas H, Palacios J, Moreno-Bueno G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene. 2007;26:2902–13.

50. Sánchez-Moreno P, Boulaz H, Ortega-Vinuesa JL, Peula-García JM, Aráneaga A. Novel drug delivery system based on docetaxel-loaded nanocapsules as a therapeutic strategy against breast cancer cells. Int J Mol Sci. 2012;13:4906–19.

51. Patel J, Amrutia J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul. 2018;35:204–17. https://doi.org/10.1080/02652048.2018.1453560.

52. Qiu M, Ouyang J, Sun H, Meng F, Cheng R, Zhang J, et al. Biodegradable micelles based on poly(ethylene glycol)-b-poly(oligoamide) copolymer: a robust and versatile nanoplatform for anticancer drug delivery. ACS Appl Mater Interfaces. 2017;9:27587–95.

53. Wu CH, Lan CH, Wu KL, Wu YM, Jane WN, Hsiao M, et al. Hepatocellular carcinoma-targeted nanoparticles for cancer therapy. Int J Oncol. 2018;52:389–401.

54. Chang DK, Li PC, Lu RM, Jane WN, Wu HC. Peptide-mediated liposomal doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models. PLoS ONE. 2013;8:e83239.

55. Kang J, Park JH, Lee HJ, Jo UI, Park JK, Seo JH, et al. Caveolin-1 modulates docetaxel-induced cell death in breast cancer cell subtypes through different mechanisms. Cancer Res Treat. 2016;48:715.

56. Liang DS, Zhang WJ, Wang AT, Su HT, Zhong HJ, Qi XR. Treating metastatic triple negative breast cancer with CDA4/neuropilin dual molecular targets of multifunctional nanoparticles. Biomaterials. 2017;137:23–36. https://doi.org/10.1016/j.biomaterials.2017.05.022.

57. Salgado R, Junius S, Benoy I, Vam Dim P, Vermeulen P, Van Marck E, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103:642–6.

58. Abana CO, Bingham BS, Cho JH, Graves AJ, Koyama T, Pilarski RT, et al. IL-6 variant is associated with metastasis in breast cancer patients. PLoS ONE. 2017;12:e0181725.

59. Oh K, Lee O, Shin SY, Nam O, Ryu PM, Seo MW. A mutual activation loop model. Breast Cancer Res. 2013;15:879.
70. Li GC, Wang ZY. Constitutive expression of RbAp46 induces epithelial–mesenchymal transition in mammary epithelial cells. Anticancer Res BMC Cancer. 2006;26:3555–60.
71. Del Bufalo D, Biocci A, Leonetti C, Zupi G. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J. 1997;11:947–53.
72. Du N, Song LP, Li XS, Wang L, Wan L, Ma HY, et al. Novel pH-sensitive nanoformulated docetaxel as a potential therapeutic strategy for the treatment of cholangiocarcinoma. J Nanobiotechnol. 2015;13:17.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions